OncoMatch/Clinical Trials/NCT06895031
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Is NCT06895031 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies JYP0015 for solid tumor.
Treatment: JYP0015 — Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Biomarker criteria
Required: HRAS mutation
Required: KRAS mutation
Required: NRAS mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: adequate standard treatment
Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06895031 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received adequate standard treatment.
Does this trial require HRAS?
Yes, HRAS mutation is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify